XML 15 R4.htm IDEA: XBRL DOCUMENT v3.10.0.1
Condensed Consolidated Statement of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2018
Sep. 30, 2017
Income Statement [Abstract]        
Revenue $ 2,362 $ 75 $ 3,242 $ 225
Operating expenses:        
Research and development 21,848 21,643 66,968 59,357
General and administrative 14,155 9,148 40,505 25,511
Total operating expenses 36,003 30,791 107,473 84,868
Loss from operations (33,641) (30,716) (104,231) (84,643)
Interest income 996 341 3,099 999
Interest expense 0 (104) (44) (439)
Change in fair value of derivative liability associated with Medicis settlement (45) (44) (150) (211)
Other expense, net (144) (128) (626) (386)
Net loss (32,834) (30,651) (101,952) (84,680)
Unrealized gain (loss) on available for sale securities 90 72 (133) 3
Comprehensive loss (32,744) (30,579) (102,085) (84,677)
Basic and Diluted net loss attributable to common stockholders $ (32,834) $ (30,651) $ (101,952) $ (84,680)
Basic and Diluted net loss per share attributable to common stockholders (Note 2) (in USD per share) $ (0.91) $ (1.01) $ (2.82) $ (2.86)
Basic and Diluted weighted-average number of shares used in computing net loss per share attributable to common stockholders (shares) 36,272,445 30,270,260 36,116,745 29,623,805